🚀 VC round data is live in beta, check it out!
Dong-E-E-Jiao Valuation Multiples
Discover revenue and EBITDA valuation multiples for Dong-E-E-Jiao and similar public comparables like Apellis Pharmaceuticals, Sumitomo Pharma, Immunovant, SK Biopharmaceuticals and more.
Dong-E-E-Jiao Overview
About Dong-E-E-Jiao
Dong-E-E-Jiao Co Ltd is a China-based company engaged in the manufacturing and selling of Chinese herbs and traditional Chinese medicines, auxiliary materials for medicine, biological and healthcare products, and genetically engineered medicines. The company's main products include donkey-hide gelatin, compound donkey-hide gelatin paste, donkey-hide gelatin cake, instant donkey-hide gelatin powder, and others.
Founded
1993
HQ
Employees
4.1K
Website
Sectors
Financials (LTM)
EV
$4B
Dong-E-E-Jiao Financials
Dong-E-E-Jiao reported last 12-month revenue of $1B and EBITDA of $320M.
In the same LTM period, Dong-E-E-Jiao generated $736M in gross profit, $320M in EBITDA, and $262M in net income.
Revenue (LTM)
Dong-E-E-Jiao P&L
In the most recent fiscal year, Dong-E-E-Jiao reported revenue of $981M and EBITDA of $325M.
Dong-E-E-Jiao expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $981M | XXX | XXX | XXX |
| Gross Profit | $736M | XXX | $721M | XXX | XXX | XXX |
| Gross Margin | 73% | XXX | 73% | XXX | XXX | XXX |
| EBITDA | $320M | XXX | $325M | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 33% | XXX | XXX | XXX |
| EBIT Margin | 30% | XXX | 30% | XXX | XXX | XXX |
| Net Profit | $262M | XXX | $255M | XXX | XXX | XXX |
| Net Margin | 26% | XXX | 26% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Dong-E-E-Jiao Stock Performance
Dong-E-E-Jiao has current market cap of $5B, and enterprise value of $4B.
Market Cap Evolution
Dong-E-E-Jiao's stock price is $8.08.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $5B | -1.9% | XXX | XXX | XXX | $0.40 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDong-E-E-Jiao Valuation Multiples
Dong-E-E-Jiao trades at 3.9x EV/Revenue multiple, and 12.1x EV/EBITDA.
EV / Revenue (LTM)
Dong-E-E-Jiao Financial Valuation Multiples
As of April 11, 2026, Dong-E-E-Jiao has market cap of $5B and EV of $4B.
Equity research analysts estimate Dong-E-E-Jiao's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dong-E-E-Jiao has a P/E ratio of 19.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV/Revenue | 3.9x | XXX | 4.0x | XXX | XXX | XXX |
| EV/EBITDA | 12.1x | XXX | 11.9x | XXX | XXX | XXX |
| EV/EBIT | 12.8x | XXX | 13.3x | XXX | XXX | XXX |
| EV/Gross Profit | 5.3x | XXX | 5.4x | XXX | XXX | XXX |
| P/E | 19.9x | XXX | 20.4x | XXX | XXX | XXX |
| EV/FCF | 14.8x | XXX | 12.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Dong-E-E-Jiao Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Dong-E-E-Jiao Margins & Growth Rates
Dong-E-E-Jiao's revenue in the last 12 month grew by 13%.
Dong-E-E-Jiao's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Dong-E-E-Jiao's rule of 40 is 44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Dong-E-E-Jiao's rule of X is 62% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Dong-E-E-Jiao Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 33% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | 9% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 44% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 62% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 32% | XXX | 32% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 7% | XXX | 7% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4% | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 44% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Dong-E-E-Jiao Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Apellis Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Sumitomo Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Immunovant | XXX | XXX | XXX | XXX | XXX | XXX |
| SK Biopharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Shanghai Junshi | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dong-E-E-Jiao M&A Activity
Dong-E-E-Jiao acquired XXX companies to date.
Last acquisition by Dong-E-E-Jiao was on XXXXXXXX, XXXXX. Dong-E-E-Jiao acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Dong-E-E-Jiao
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDong-E-E-Jiao Investment Activity
Dong-E-E-Jiao invested in XXX companies to date.
Dong-E-E-Jiao made its latest investment on XXXXXXXX, XXXXX. Dong-E-E-Jiao invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Dong-E-E-Jiao
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Dong-E-E-Jiao
| When was Dong-E-E-Jiao founded? | Dong-E-E-Jiao was founded in 1993. |
| Where is Dong-E-E-Jiao headquartered? | Dong-E-E-Jiao is headquartered in China. |
| How many employees does Dong-E-E-Jiao have? | As of today, Dong-E-E-Jiao has over 4K employees. |
| Is Dong-E-E-Jiao publicly listed? | Yes, Dong-E-E-Jiao is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Dong-E-E-Jiao? | Dong-E-E-Jiao trades under 000423 ticker. |
| When did Dong-E-E-Jiao go public? | Dong-E-E-Jiao went public in 1996. |
| Who are competitors of Dong-E-E-Jiao? | Dong-E-E-Jiao main competitors are Apellis Pharmaceuticals, Sumitomo Pharma, Immunovant, SK Biopharmaceuticals. |
| What is the current market cap of Dong-E-E-Jiao? | Dong-E-E-Jiao's current market cap is $5B. |
| What is the current revenue of Dong-E-E-Jiao? | Dong-E-E-Jiao's last 12 months revenue is $1B. |
| What is the current revenue growth of Dong-E-E-Jiao? | Dong-E-E-Jiao revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Dong-E-E-Jiao? | Current revenue multiple of Dong-E-E-Jiao is 3.9x. |
| Is Dong-E-E-Jiao profitable? | Yes, Dong-E-E-Jiao is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Dong-E-E-Jiao? | Dong-E-E-Jiao's last 12 months EBITDA is $320M. |
| What is Dong-E-E-Jiao's EBITDA margin? | Dong-E-E-Jiao's last 12 months EBITDA margin is 32%. |
| What is the current EV/EBITDA multiple of Dong-E-E-Jiao? | Current EBITDA multiple of Dong-E-E-Jiao is 12.1x. |
| What is the current FCF of Dong-E-E-Jiao? | Dong-E-E-Jiao's last 12 months FCF is $262M. |
| What is Dong-E-E-Jiao's FCF margin? | Dong-E-E-Jiao's last 12 months FCF margin is 26%. |
| What is the current EV/FCF multiple of Dong-E-E-Jiao? | Current FCF multiple of Dong-E-E-Jiao is 14.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.